Total Payments
$2,063
2024 Payments
$121.62
Companies
21
Transactions
130
Medicare Patients
1,583
Medicare Billing
$219,584
Payment Breakdown by Category
Food & Beverage$1,844 (89.4%)
Education$201.52 (9.8%)
Travel$17.69 (0.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,844 | 125 | 89.4% |
| Education | $201.52 | 4 | 9.8% |
| Travel and Lodging | $17.69 | 1 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $541.83 | 49 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $272.35 | 19 | $0 (2018) |
| PFIZER INC. | $242.36 | 14 | $0 (2024) |
| Amgen Inc. | $155.01 | 5 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $135.79 | 2 | $0 (2021) |
| Incyte Corporation | $111.08 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $109.33 | 7 | $0 (2018) |
| Celgene Corporation | $106.79 | 6 | $0 (2018) |
| Janssen Biotech, Inc. | $78.71 | 6 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $74.39 | 6 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $121.62 | 3 | Incyte Corporation ($83.99) |
| 2023 | $134.04 | 6 | Karyopharm Therapeutics Inc. ($41.87) |
| 2022 | $18.67 | 1 | Karyopharm Therapeutics Inc. ($18.67) |
| 2021 | $231.83 | 3 | AstraZeneca Pharmaceuticals LP ($120.80) |
| 2019 | $45.67 | 3 | Genentech USA, Inc. ($45.67) |
| 2018 | $517.00 | 38 | Genentech USA, Inc. ($182.88) |
| 2017 | $994.24 | 76 | Genentech USA, Inc. ($313.28) |
All Payment Transactions
130 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $83.99 | General |
| 07/18/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: Oncology | ||||||
| 10/31/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: Oncology | ||||||
| 09/19/2023 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $27.09 | General |
| Category: Oncology | ||||||
| 09/12/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Oncology | ||||||
| 05/04/2023 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 04/06/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: Oncology | ||||||
| 01/10/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.68 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2022 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Oncology | ||||||
| 07/08/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $120.80 | General |
| Category: Oncology | ||||||
| 04/02/2021 | Amgen Inc. | — | Education | In-kind items and services | $99.99 | General |
| 03/18/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $11.04 | General |
| Category: Oncology | ||||||
| 09/19/2019 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: BioOncology | ||||||
| 08/15/2019 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: BioOncology | ||||||
| 06/13/2019 | Genentech USA, Inc. | GAZYVA (Biological) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: BioOncology | ||||||
| 07/19/2018 | Genentech USA, Inc. | GAZYVA (Biological), Rituxan Hycela | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: BioOncology | ||||||
| 06/28/2018 | Genentech USA, Inc. | GAZYVA (Biological), Rituxan Hycela | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: BioOncology | ||||||
| 06/21/2018 | Genentech USA, Inc. | GAZYVA (Biological) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: BioOncology | ||||||
| 06/14/2018 | PFIZER INC. | SUTENT (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 06/11/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $11.90 | General |
| 05/16/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2018 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $14.46 | General |
| Category: BioOncology | ||||||
| 04/30/2018 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Oncology | ||||||
| 04/19/2018 | Novartis Pharmaceuticals Corporation | VOTRIENT (Drug) | Food and Beverage | In-kind items and services | $12.52 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 367 | 649 | $253,845 | $64,190 |
| 2022 | 10 | 396 | 632 | $204,984 | $49,948 |
| 2021 | 10 | 423 | 780 | $206,210 | $53,921 |
| 2020 | 8 | 397 | 792 | $185,562 | $51,526 |
Total Patients
1,583
Total Services
2,853
Medicare Billing
$219,584
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 66 | 216 | $114,108 | $28,990 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 88 | 136 | $51,007 | $12,184 | 23.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 69 | $22,908 | $6,348 | 27.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 44 | 85 | $18,928 | $5,012 | 26.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $14,899 | $3,748 | 25.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 19 | $10,079 | $2,590 | 25.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $7,330 | $1,943 | 26.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $6,827 | $1,559 | 22.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 26 | $6,888 | $1,472 | 21.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 36 | 42 | $871.00 | $344.40 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 98 | 197 | $72,338 | $17,024 | 23.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 48 | 88 | $46,889 | $11,987 | 25.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 49 | 96 | $19,541 | $5,093 | 26.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 37 | 65 | $19,270 | $4,934 | 25.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 60 | 68 | $17,614 | $3,495 | 19.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $10,448 | $2,554 | 24.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $7,664 | $1,966 | 25.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 21 | 21 | $6,054 | $1,569 | 25.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $4,689 | $1,172 | 25.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 39 | 53 | $477.00 | $154.19 | 32.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 85 | 238 | $88,060 | $22,639 | 25.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 72 | 180 | $36,180 | $10,012 | 27.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 88 | 120 | $31,320 | $7,262 | 23.2% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 42 | 46 | $12,972 | $3,501 | 27.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 42 | $12,096 | $3,412 | 28.2% |
About Dr. Amjad Jalil, M.D
Dr. Amjad Jalil, M.D is a Hematology & Oncology healthcare provider based in Clairton, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356391841.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amjad Jalil, M.D has received a total of $2,063 in payments from pharmaceutical and medical device companies, with $121.62 received in 2024. These payments were reported across 130 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($1,844).
As a Medicare-enrolled provider, Jalil has provided services to 1,583 Medicare beneficiaries, totaling 2,853 services with total Medicare billing of $219,584. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Clairton, PA
- Active Since 05/12/2006
- Last Updated 10/09/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356391841
Products in Payments
- TECENTRIQ (Biological) $171.48
- Avastin (Biological) $127.39
- IMFINZI (Biological) $120.80
- KEYTRUDA (Biological) $91.49
- SUTENT (Drug) $90.42
- Abraxane (Drug) $82.79
- GAZYVA (Biological) $81.06
- ELIQUIS (Drug) $68.89
- Herceptin (Biological) $68.44
- XPOVIO (Drug) $60.54
- BOSULIF (Drug) $52.08
- ZYTIGA (Drug) $51.32
- OPDIVO (Biological) $47.61
- ADCETRIS (Biological) $45.90
- Perjeta (Biological) $41.80
- MEKINIST (Drug) $39.12
- VOTRIENT (Drug) $36.55
- VENCLEXTA (Biological) $34.98
- Enhertu (Drug) $28.68
- MONJUVI (Drug) $27.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.